AHNAK2 is a biomarker and a potential therapeutic target of adenocarcinomas
Adenocarcinoma is the second largest histological type of cervical cancer, second only to cervical squamous cell carcinoma. At present, despite the clinical treatment strategies of cervical adenocarcinoma and cervical squamous cell carcinoma being similar, the outcome and prognosis of cervical adeno...
Main Authors: | Xu Meng, Cheng Anyi, Yu Liya, Wei Wei, Li Jinpeng, Cai Cheguo |
---|---|
Format: | Article |
Language: | English |
Published: |
China Science Publishing & Media Ltd.
2022-08-01
|
Series: | Acta Biochimica et Biophysica Sinica |
Subjects: | |
Online Access: | https://www.sciengine.com/doi/10.3724/abbs.2022112 |
Similar Items
-
The Obscure Potential of AHNAK2
by: Mohamed Zardab, et al.
Published: (2022-01-01) -
AHNAKs roles in physiology and malignant tumors
by: Shusen Zhang, et al.
Published: (2023-11-01) -
Downregulation of AHNAK2 inhibits cell cycle of lung adenocarcinoma cells by interacting with RUVBL1
by: Xin Li, et al.
Published: (2023-08-01) -
Prognostic Impact of AHNAK2 Expression in Patients Treated with Radical Cystectomy
by: Dai Koguchi, et al.
Published: (2021-04-01) -
AHNAK suppresses tumour proliferation and invasion by targeting multiple pathways in triple-negative breast cancer
by: Bo Chen, et al.
Published: (2017-05-01)